Protein kinase C θ (PKC θ) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)

Anette Duensing, Nora E. Joseph, Fabiola Medeiros, Felicity Smith, Jason L. Hornick, Michael Heinrich, Christopher Corless, George D. Demetri, Christopher D M Fletcher, Jonathan A. Fletcher

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

KIT expression is a key diagnostic feature of gastrointestinal stromal tumors (GISTs), and virtually all of the GISTs express oncogenic forms of the KIT or PDGFRA receptor tyrosine kinase proteins, which serve as therapeutic targets of imatinin mesylate (Gleevec; Novartis, Basel, Switzerland). However, KIT expression can be low in PDGFRA-mutant GISTs, increasing the likelihood of misdiagnosis as other types of sarcoma. We report that the signaling intermediate protein kinase C θ (PKCθ) is a diagnostic marker in GISTs, including those that lack KIT expression and/or contain PDGFRA mutations. PKCθ is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target.

Original languageEnglish (US)
Pages (from-to)5127-5131
Number of pages5
JournalCancer Research
Volume64
Issue number15
DOIs
StatePublished - Aug 1 2004

Fingerprint

Gastrointestinal Stromal Tumors
Protein Kinase C
Mesylates
Receptor Protein-Tyrosine Kinases
Diagnostic Errors
Switzerland
Sarcoma
Mutation
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Protein kinase C θ (PKC θ) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). / Duensing, Anette; Joseph, Nora E.; Medeiros, Fabiola; Smith, Felicity; Hornick, Jason L.; Heinrich, Michael; Corless, Christopher; Demetri, George D.; Fletcher, Christopher D M; Fletcher, Jonathan A.

In: Cancer Research, Vol. 64, No. 15, 01.08.2004, p. 5127-5131.

Research output: Contribution to journalArticle

Duensing, A, Joseph, NE, Medeiros, F, Smith, F, Hornick, JL, Heinrich, M, Corless, C, Demetri, GD, Fletcher, CDM & Fletcher, JA 2004, 'Protein kinase C θ (PKC θ) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)', Cancer Research, vol. 64, no. 15, pp. 5127-5131. https://doi.org/10.1158/0008-5472.CAN-04-0559
Duensing, Anette ; Joseph, Nora E. ; Medeiros, Fabiola ; Smith, Felicity ; Hornick, Jason L. ; Heinrich, Michael ; Corless, Christopher ; Demetri, George D. ; Fletcher, Christopher D M ; Fletcher, Jonathan A. / Protein kinase C θ (PKC θ) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). In: Cancer Research. 2004 ; Vol. 64, No. 15. pp. 5127-5131.
@article{2abd92f93e4c409bb553f5c5adc8cd8b,
title = "Protein kinase C θ (PKC θ) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)",
abstract = "KIT expression is a key diagnostic feature of gastrointestinal stromal tumors (GISTs), and virtually all of the GISTs express oncogenic forms of the KIT or PDGFRA receptor tyrosine kinase proteins, which serve as therapeutic targets of imatinin mesylate (Gleevec; Novartis, Basel, Switzerland). However, KIT expression can be low in PDGFRA-mutant GISTs, increasing the likelihood of misdiagnosis as other types of sarcoma. We report that the signaling intermediate protein kinase C θ (PKCθ) is a diagnostic marker in GISTs, including those that lack KIT expression and/or contain PDGFRA mutations. PKCθ is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target.",
author = "Anette Duensing and Joseph, {Nora E.} and Fabiola Medeiros and Felicity Smith and Hornick, {Jason L.} and Michael Heinrich and Christopher Corless and Demetri, {George D.} and Fletcher, {Christopher D M} and Fletcher, {Jonathan A.}",
year = "2004",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-04-0559",
language = "English (US)",
volume = "64",
pages = "5127--5131",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Protein kinase C θ (PKC θ) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)

AU - Duensing, Anette

AU - Joseph, Nora E.

AU - Medeiros, Fabiola

AU - Smith, Felicity

AU - Hornick, Jason L.

AU - Heinrich, Michael

AU - Corless, Christopher

AU - Demetri, George D.

AU - Fletcher, Christopher D M

AU - Fletcher, Jonathan A.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - KIT expression is a key diagnostic feature of gastrointestinal stromal tumors (GISTs), and virtually all of the GISTs express oncogenic forms of the KIT or PDGFRA receptor tyrosine kinase proteins, which serve as therapeutic targets of imatinin mesylate (Gleevec; Novartis, Basel, Switzerland). However, KIT expression can be low in PDGFRA-mutant GISTs, increasing the likelihood of misdiagnosis as other types of sarcoma. We report that the signaling intermediate protein kinase C θ (PKCθ) is a diagnostic marker in GISTs, including those that lack KIT expression and/or contain PDGFRA mutations. PKCθ is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target.

AB - KIT expression is a key diagnostic feature of gastrointestinal stromal tumors (GISTs), and virtually all of the GISTs express oncogenic forms of the KIT or PDGFRA receptor tyrosine kinase proteins, which serve as therapeutic targets of imatinin mesylate (Gleevec; Novartis, Basel, Switzerland). However, KIT expression can be low in PDGFRA-mutant GISTs, increasing the likelihood of misdiagnosis as other types of sarcoma. We report that the signaling intermediate protein kinase C θ (PKCθ) is a diagnostic marker in GISTs, including those that lack KIT expression and/or contain PDGFRA mutations. PKCθ is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=3442881363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442881363&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-0559

DO - 10.1158/0008-5472.CAN-04-0559

M3 - Article

VL - 64

SP - 5127

EP - 5131

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 15

ER -